BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29396853)

  • 1. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
    Adler NR; Murray WK; Brady B; McCormack C; Pan Y
    Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
    [No Abstract]   [Full Text] [Related]  

  • 2. Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma.
    Kyllo RL; Parker MK; Rosman I; Musiek AC
    J Am Acad Dermatol; 2014 Apr; 70(4):e85-e86. PubMed ID: 24629370
    [No Abstract]   [Full Text] [Related]  

  • 3. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
    Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
    Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
    [No Abstract]   [Full Text] [Related]  

  • 4. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
    Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
    [No Abstract]   [Full Text] [Related]  

  • 6. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
    Majenka P; Hoffmann M; Rötzer I; Dimitrakopoulou-Strauss A; Koschny R; Longerich T; Enk A; Hassel JC
    Eur J Cancer; 2019 Jan; 106():220-224. PubMed ID: 30528806
    [No Abstract]   [Full Text] [Related]  

  • 7. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
    Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
    [No Abstract]   [Full Text] [Related]  

  • 9. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
    Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
    J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
    [No Abstract]   [Full Text] [Related]  

  • 11. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
    Donaldson M; Owen JL; Choi JN
    JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
    [No Abstract]   [Full Text] [Related]  

  • 12. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.
    Dika E; Ravaioli GM; Fanti PA; Piraccini BM; Lambertini M; Chessa MA; Baraldi C; Ribero S; Andrea A; Melotti B; Patrizi A
    Eur J Dermatol; 2017 Jun; 27(3):266-270. PubMed ID: 28524050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
    Alniemi DT; Fischer A; Greene LA; Pierson JC
    Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab-associated Sweet syndrome in a melanoma patient.
    Gormley R; Wanat K; Elenitsas R; Giles J; McGettigan S; Schuchter L; Takeshita J
    J Am Acad Dermatol; 2014 Nov; 71(5):e211-3. PubMed ID: 25437997
    [No Abstract]   [Full Text] [Related]  

  • 15. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
    Mandalà M; Merelli B; Indriolo A; Tondini C
    Eur J Cancer; 2018 May; 95():130-132. PubMed ID: 29559189
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab.
    Oishi K; Nakao M; Maeda S; Matsushita T; Ikeda T; Yamada T; Takehara K; Hamaguchi Y
    Eur J Dermatol; 2017 Apr; 27(2):193-194. PubMed ID: 28007669
    [No Abstract]   [Full Text] [Related]  

  • 17. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 18. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
    Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K
    J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
    Witmer MT
    Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
    Sato M; Uhara H; Koga H; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.